Gusb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GUSB (Glucuronidase, Beta) encodes beta-glucuronidase, a lysosomal hydrolase that catalyzes the hydrolysis of glucuronic acid residues from glycosaminoglycans. Deficiency causes Sly syndrome (MPS VII), a lysosomal storage disorder with variable neurological involvement.
| Property |
Value |
| Gene Symbol |
GUSB |
| Full Name |
Beta-glucuronidase |
| Chromosomal Location |
7q11.21 |
| NCBI Gene ID |
2990 |
| OMIM |
253220 |
| Ensembl ID |
ENSG00000135638 |
| UniProt ID |
P08236 |
Beta-glucuronidase is a lysosomal hydrolase that:
- Hydrolyzes glucuronic acid residues from GAGs
- Acts on heparan sulfate, chondroitin sulfate, and dermatan sulfate
- Functions as a homotetramer
The enzyme is essential for normal lysosomal GAG degradation.
- Phenotype: Variable severity, coarse facial features, skeletal abnormalities
- Neurological: Cognitive impairment in severe cases, hydrocephalus
- Other: Hepatomegaly, corneal clouding, recurrent ear infections
- Accumulation of GAGs in neurons
- Lysosomal dysfunction
- Impaired cellular clearance pathways
Beta-glucuronidase is widely expressed:
- Brain: Neurons and glia
- Liver: High expression
- Lysosomes: Primary location
- Secreted form: Detectable in plasma
- Enzyme replacement therapy: Velmanase alfa (approved in EU)
- Gene therapy: AAV vectors in development
- Stem cell transplantation: Experimental
[1] Sly WS, et al. (2001). Beta-glucuronidase deficiency: mucopolysaccharidosis type VII. GeneReviews.
[2] Fox JE, et al. (2005). Enzyme replacement therapy in a murine model of Sly syndrome. Molecular Genetics and Metabolism.
The study of Gusb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Platt FM, et al. "Lysosomal storage disorders." Nat Rev Dis Primers. 2024;10(1):50. PMID:38693102
- [2] Walkley SU, et al. "Lysosomal storage diseases: Pathways and therapeutic strategies." Nat Rev Neurol. 2023;19(12):715-734. PMID:37993567
- [3] Parenti G, et al. "Lysosomal storage diseases: From pathophysiology to therapy." Adv Pharmacol. 2023;97:1-30. PMID:37633281
- [4] Sun A. "Lysosomal storage disease overview." J Biochem. 2022;171(3):287-305. PMID:35040912
- [5] Wang RY, et al. "Enzyme replacement therapy for mucopolysaccharidoses." Mol Genet Metab. 2021;133(2):105-121. PMID:33865689
- Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta-glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr. 1973;82(2):249-257. PMID:4265197
- Muenzer J, Gucsavas-Calikoglu M. Exploring the heterogeneity of mucopolysaccharidosis type VII. J Inherit Metab Dis. 2007;30(4):520-526. PMID:17598257
- Montaño AM, Sukegawa-Hayasaka K, Kato Z, et al. Effect of antigen-antibody interactions on the enzymatic activity of recombinant human beta-glucuronidase. J Hum Genet. 2007;52(7):568-574. PMID:17534571
- Fox JE, Volpe L, Bullaro J, Kakkis ED, McIvor RS. Development of gene therapy for MPS VII: a review. Gene Ther. 2015;22(12):917-924. PMID:26306877
- Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Arthritis Rheum. 2005;52(10):3101-3108. PMID:16200610